• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Certification, Purchasing and Quality Assurance

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • Important Items in China Pre-NDA Meetings for Innovative Drug Approvals

Important Items in China Pre-NDA Meetings for Innovative Drug Approvals

Monday, 20 December 2021 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Important Items in China Pre-NDA Meetings for Innovative Drug Approvals

On November 26, 2021, the CDE (Center for Drug Evaluation) under the NMPA (National Medical Products Administration) published (No.48-2021) the technical requirements including common pharmacology issues for Pre-NDA meetings prior to innovative drugs going to market.

The Pre-NDA meeting is important to the approval of the NDA (New Drug Application) whilst focusing on key areas beneficial to the launch of new drug products, and providing applicants with ideas to improve the quality and efficiency of communication between applicants and the regulator.

The technical requirements addressed the following common issues:

  • API synthesis starting material selection
  • API pharmacological change research
  • API-related substances research and control
  • Research on mutagenic impurities
  • API quality control projects
  • Formulation change studies
  • Formulation degradation impurity research
  • Formulation quality control program and formulation dissolution
  • Release studies and other aspects of common pharmacy issues and general requirements

The technical requirement also stressed that major pharmacological changes should be completed as soon as possible before the start of clinical trials. If major pharmacological changes occur after the end of the clinical trial, the drug registration process may be affected.

In order to encourage the R&D and submission to accelerate the marketing process of innovative drugs, the NMPA supports applicants to resolve pharmacology-related issues during clinical trials through communication channels such as pre-application meeting for new drug clinical trials (Pre-IND meeting), end of phase II clinical trial for new drugs (EOP II)/pre-initiation meeting for phase III clinical trials (Pre-III meeting) at different research stages.

By Sun Jinlin and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: drugs, Innovative drugs, NDA, New Drug Applications, Pre-NDA

What you can read next

NMPA Develops API Production and Supply Information Collection Platform
Cosmetics Sample Test
NHC Approves 15 New Food Materials

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • cosmetics-gmp

    Cosmetics GMP Good Manufacturing Practices now in force in China

    Cosmetics GMP in China came into force on July ...
  • china-vaccine-production

    China vaccine production and distribution rules released

    China Vaccine Production and Distribution Rules...
  • Technical Guidelines Essential Principles

    Technical Guidelines for Essential Principles of Safety and Performance of Medical Devices

    Technical Guidelines for Essential Principles o...
  • China drug real-world study design

    China drug real-world study design and protocol framework guidelines is open for comments

    China drug real-world study design and protocol...
  • contract manufacturing of Hong Kong medical device and drug in GBA

    Contract manufacturing of Hong Kong medical device and drug in GBA supported by China NMPA

    Contract manufacturing of Hong Kong medical dev...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.